Literature DB >> 20600450

Transcript abundance patterns in Kawasaki disease patients with intravenous immunoglobulin resistance.

Wen Fury1, Adriana H Tremoulet, Virginia E Watson, Brookie M Best, Chisato Shimizu, Jennifer Hamilton, John T Kanegaye, Yi Wei, Chiayi Kao, Scott Mellis, Calvin Lin, Jane C Burns.   

Abstract

Intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD) patients comprise at least 20% of treated patients and are at high risk for coronary artery abnormalities. If identified early in the course of the disease, such patients may benefit from additional anti-inflammatory therapy. The aim of this study was to compare the transcript abundance between IVIG resistant and -responsive KD patients, to identify biomarkers that might differentiate between these two groups and to generate new targets for therapies in IVIG resistant KD patients. We compared the transcript abundance profiles of whole-blood RNA on Agilent arrays from acute and convalescent KD subjects and age-similar, healthy controls. KD subjects were stratified as IVIG resistant or -responsive based on response to initial IVIG therapy. Transcript abundance was higher for IL-1 pathway genes (IL-1 receptor, interleukin receptor associated kinase, p38 mitogen-activated protein kinase), and MMP-8. These findings point to candidate biomarkers that may predict IVIG resistance in acute KD patients. The results also underscore the importance of the IL-1 pathway as a mediator of inflammation in KD and suggest that IL-1 or its receptor may be reasonable targets for therapy, particularly for IVIG resistant patients. Copyright 2010 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20600450      PMCID: PMC2929310          DOI: 10.1016/j.humimm.2010.06.008

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  45 in total

Review 1.  S100 proteins in the pathogenesis of Kawasaki disease.

Authors:  Jane C Burns
Journal:  J Am Coll Cardiol       Date:  2006-08-28       Impact factor: 24.094

2.  Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease.

Authors:  Jane C Burns; Brookie M Best; Asuncion Mejias; Lynn Mahony; David E Fixler; Hasan S Jafri; Marian E Melish; Mary Anne Jackson; Basim I Asmar; David J Lang; James D Connor; Edmund V Capparelli; Monica L Keen; Khalid Mamun; Gregory F Keenan; Octavio Ramilo
Journal:  J Pediatr       Date:  2008-07-30       Impact factor: 4.406

3.  Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment.

Authors:  Tetsuya Sano; Shunji Kurotobi; Kouji Matsuzaki; Takehisa Yamamoto; Ichiro Maki; Kazunori Miki; Shigetoyo Kogaki; Junichi Hara
Journal:  Eur J Pediatr       Date:  2006-08-01       Impact factor: 3.183

4.  Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements.

Authors:  Brian W McCrindle; Jennifer S Li; L LuAnn Minich; Steven D Colan; Andrew M Atz; Masato Takahashi; Victoria L Vetter; Welton M Gersony; Paul D Mitchell; Jane W Newburger
Journal:  Circulation       Date:  2007-06-18       Impact factor: 29.690

5.  Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.

Authors:  Hal M Hoffman; Martin L Throne; N J Amar; Mohamed Sebai; Alan J Kivitz; Arthur Kavanaugh; Steven P Weinstein; Pavel Belomestnov; George D Yancopoulos; Neil Stahl; Scott J Mellis
Journal:  Arthritis Rheum       Date:  2008-08

6.  Resistance to intravenous immunoglobulin in children with Kawasaki disease.

Authors:  Adriana H Tremoulet; Brookie M Best; Sungchan Song; Susan Wang; Elena Corinaldesi; Julia R Eichenfield; Danielle D Martin; Jane W Newburger; Jane C Burns
Journal:  J Pediatr       Date:  2008-03-04       Impact factor: 4.406

7.  Increased matrix metalloproteinase-8 and -9 activity in patients with infarct rupture after myocardial infarction.

Authors:  Susanne W M van den Borne; Jack P M Cleutjens; Roeland Hanemaaijer; Esther E Creemers; Jos F M Smits; Mat J A P Daemen; W Matthijs Blankesteijn
Journal:  Cardiovasc Pathol       Date:  2008-03-04       Impact factor: 2.185

8.  Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan.

Authors:  Ritei Uehara; Ermias D Belay; Ryan A Maddox; Robert C Holman; Yosikazu Nakamura; Mayumi Yashiro; Izumi Oki; Hirotaro Ogino; Lawrence B Schonberger; Hiroshi Yanagawa
Journal:  Pediatr Infect Dis J       Date:  2008-02       Impact factor: 2.129

9.  Tissue inhibitor of metalloproteinase 2 and coronary artery lesions in Kawasaki disease.

Authors:  Kenji Furuno; Hidetoshi Takada; Ken Yamamoto; Kazuyuki Ikeda; Takuro Ohno; Vahid Khajoee; Yumi Mizuno; Toshiro Hara
Journal:  J Pediatr       Date:  2007-06-15       Impact factor: 4.406

10.  Gene-expression patterns reveal underlying biological processes in Kawasaki disease.

Authors:  Stephen J Popper; Chisato Shimizu; Hiroko Shike; John T Kanegaye; Jane W Newburger; Robert P Sundel; Patrick O Brown; Jane C Burns; David A Relman
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

View more
  33 in total

Review 1.  Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics.

Authors:  Romain Banchereau; Alma-Martina Cepika; Jacques Banchereau; Virginia Pascual
Journal:  Annu Rev Immunol       Date:  2017-01-30       Impact factor: 28.527

2.  Identification of Differentially Expressed Genes in Kawasaki Disease Patients as Potential Biomarkers for IVIG Sensitivity by Bioinformatics Analysis.

Authors:  Lan He; Youyu Sheng; Chunyun Huang; Guoying Huang
Journal:  Pediatr Cardiol       Date:  2016-05-09       Impact factor: 1.655

Review 3.  Intravascular immunity as a key to systemic vasculitis: a work in progress, gaining momentum.

Authors:  G A Ramirez; N Maugeri; M G Sabbadini; P Rovere-Querini; A A Manfredi
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

4.  Interleukin-1β is crucial for the induction of coronary artery inflammation in a mouse model of Kawasaki disease.

Authors:  Youngho Lee; Danica J Schulte; Kenichi Shimada; Shuang Chen; Timothy R Crother; Norika Chiba; Michael C Fishbein; Thomas J A Lehman; Moshe Arditi
Journal:  Circulation       Date:  2012-02-23       Impact factor: 29.690

5.  Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysm.

Authors:  Adriana H Tremoulet; Sonia Jain; Pei-Ni Jone; Brookie M Best; Elizabeth H Duxbury; Alessandra Franco; Beth Printz; Samuel R Dominguez; Heather Heizer; Marsha S Anderson; Mary P Glodé; Feng He; Robert L Padilla; Chisato Shimizu; Emelia Bainto; Joan Pancheri; Harvey J Cohen; John C Whitin; Jane C Burns
Journal:  J Pediatr       Date:  2019-09-24       Impact factor: 4.406

6.  Immunoglobulin Resistance in Kawasaki Disease.

Authors:  Georgios A Hartas; Syed Shahrukh Hashmi; Chi Pham-Peyton; Emmanouil Tsounias; John T Bricker; Monesha Gupta-Malhotra
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2015-03-01       Impact factor: 1.349

Review 7.  Treatment Options for Resistant Kawasaki Disease.

Authors:  Linny Kimly Phuong; Nigel Curtis; Peter Gowdie; Jonathan Akikusa; David Burgner
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

Review 8.  Review: Found in Translation: International Initiatives Pursuing Interleukin-1 Blockade for Treatment of Acute Kawasaki Disease.

Authors:  Jane C Burns; Isabelle Koné-Paut; Taco Kuijpers; Chisato Shimizu; Adriana Tremoulet; Moshe Arditi
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995

9.  Transforming growth factor-beta signaling pathway in patients with Kawasaki disease.

Authors:  Chisato Shimizu; Sonia Jain; Sonia Davila; Martin L Hibberd; Kevin O Lin; Delaram Molkara; Jeffrey R Frazer; Shelly Sun; Annette L Baker; Jane W Newburger; Anne H Rowley; Stanford T Shulman; Sonia Davila; David Burgner; Willemijn B Breunis; Taco W Kuijpers; Victoria J Wright; Michael Levin; Hariklia Eleftherohorinou; Lachlan Coin; Stephen J Popper; David A Relman; Wen Fury; Calvin Lin; Scott Mellis; Adriana H Tremoulet; Jane C Burns
Journal:  Circ Cardiovasc Genet       Date:  2010-12-02

Review 10.  Intravenous immunoglobulin therapy in rheumatic diseases.

Authors:  Jagadeesh Bayry; Vir Singh Negi; Srini V Kaveri
Journal:  Nat Rev Rheumatol       Date:  2011-05-10       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.